Author

Arumugan Nallasivan

Observed name: A Nallasivan

Observed institutions: The University of Sydney, Cliniques Universitaires Saint-Luc, The University of Western Australia, Salford Royal NHS Foundation Trust, James Cook University Hospital, Danderyds sjukhus, Westmead Hospital, Ospedale Sacro Cuore Don Calabria, The George Institute for Global Health, University of Edinburgh

OpenAlex ID: A5035171872

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 493

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 369

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 290

Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke

2015 · Grant Mair, Rüdiger von Kummer, et al. · Neurology · 40

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 39

Sex Differences in Outcomes After Tenecteplase for Minor Stroke: A Subanalysis of the TEMPO‐2 Trial

2025 · Amy Y. X. Yu, Shabnam Vatanpour, et al. · Journal of the American Heart Association · 2

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases

Works count: 7

Citation count: 1,232

H-index: 5

I10-index: 5